Merck's earnings call highlights strong performance, particularly in KEYTRUDA and GARDASIL, driving revenue growth above expectations.  Management expressed confidence in the company's future, emphasizing the strength of its pipeline and the potential of new acquisitions.  The inclusion of a significant one-time charge from the Prometheus acquisition, however, impacts the short-term financial picture.
[1]
